The prognostic value of HER-2/neu overexpression in colorectal cancer: evidence from 16 studies

Tumor Biology

Volumn 35, Issue 11, 2014, Pages 10799-10804

  Wu, Sheng wen ^a   Ma, Cong chao ^a   Yang, Yu ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

Colorectal cancer; HER 2 neu; Meta analysis; Prognosis; Survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

AGED; CASE CONTROL STUDY; COLORECTAL NEOPLASMS; HUMAN; META ANALYSIS (TOPIC); METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; SURVIVAL RATE;

AGED; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; HUMANS; META-ANALYSIS AS TOPIC; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; SURVIVAL RATE;

EID: 84928588455     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2376-0     Document Type: Article

References (35)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.
2. Xu AG, Yu ZJ, Jiang B, Wang XY, Zhong XH, Liu JH, et al. Colorectal cancer in Guangdong Province of china: a demographic and anatomic survey. World J Gastroenterol WJG. 2010;16:960–5.
3. Hynes NE, Lane HA. Erbb receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341–54.
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–82.
5. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–12.
6. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365:1273–83.
7. Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med. 2007;26:53–77.
8. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
9. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.
10. Baiocchi G, Lopes A, Coudry RA, Rossi BM, Soares FA, Aguiar S, et al. Erbb family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery. Int J Color Dis. 2009;24:1059–68.
11. Chen J, Li Q, Wang C, Wu J, Zhao G. Prognostic significance of c-erbb-2 and vascular endothelial growth factor in colorectal liver metastases. Ann Surg Oncol. 2010;17:1555–63.
12. Conradi LC, Styczen H, Sprenger T, Wolff HA, Rodel C, Nietert M, et al. Frequency of HER-2 positivity in rectal cancer and prognosis. Am J Surg Pathol. 2013;37:522–31.
13. Ismail HM, El-Baradie M, Moneer M, Khorshid O, Touny A. Clinico-pathological and prognostic significance of p53, bcl-2 and Her-2/neu protein markers in colorectal cancer using tissue microarray. J Egypt Nat Cancer Inst. 2007;19:3–14.
14. Jesus EC, Matos D, Artigiani R, Waitzberg AF, Goldenberg A, Saad SS. Assessment of staging, prognosis and mortality of colorectal cancer by tumor markers: Receptor erbb-2 and cadherins. Acta Cir Bras Soc Bras Desenvolvimento Pesq Cir. 2005;20:422–7.
15. Kavanagh DO, Chambers G, O’Grady L, Barry KM, Waldron RP, Bennani F, et al. Is overexpression of her-2 a predictor of prognosis in colorectal cancer? BMC Cancer. 2009;9:1.
16. Lazaris AC, Theodoropoulos GE, Anastassopoulos P, Nakopoulou L, Panoussopoulos D, Papadimitriou K. Prognostic significance of p53 and c-erbb-2 immunohistochemical evaluation in colorectal adenocarcinoma. Histol Histopathol. 1995;10:661–8.
17. Li Q, Wang D, Li J, Chen P. Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas. BMC Cancer. 2011;11:277.
18. Lim SW, Kim HR, Kim HY, Huh JW, Kim YJ, Shin JH, et al. Over-expression of Her-2 in colorectal cancer tissue, but not in serum, constitutes an independent worse prognostic factor. Cell Oncol. 2013;36:311–21.
19. Lu Y, Jingyan G, Baorong S, Peng J, Xu Y, Cai S. Expression of EGFR, Her2 predict lymph node metastasis (LNM)-associated metastasis in colorectal cancer. Cancer Biomark Sect A Dis MarkersMarker. 2012;11:219–26.
20. McKay JA, Loane JF, Ross VG, Ameyaw MM, Murray GI, Cassidy J, et al. C-erbb-2 is not a major factor in the development of colorectal cancer. Br J Cancer. 2002;86:568–73.
21. Osako T, Miyahara M, Uchino S, Inomata M, Kitano S, Kobayashi M. Immunohistochemical study of c-erbb-2 protein in colorectal cancer and the correlation with patient survival. Oncology. 1998;55:548–55.
22. Pappas A, Lagoudianakis E, Seretis C, Tsiambas E, Koronakis N, Toutouzas K, et al. Clinical role of HER-2/neu expression in colorectal cancer. J BUON Off J Balk Union of Oncol. 2013;18:98–104.
23. Park DI, Kang MS, Oh SJ, Kim HJ, Cho YK, Sohn CI, et al. HER-2/neu overexpression is an independent prognostic factor in colorectal cancer. Int J Color Dis. 2007;22:491–7.
24. Rossi HA, Liu Q, Banner B, Hsieh CC, Savas L, Savarese D. The prognostic value of invariant chain (ii) and Her-2/neu expression in curatively resected colorectal cancer. Cancer J. 2002;8:268–75.
25. Shin IY, Sung NY, Lee YS, Kwon TS, Si Y, Lee YS, et al. The expression of multiple proteins as prognostic factors in colorectal cancer: cathepsin D, p53, COX-2, epidermal growth factor receptor, C-erbB-2, and Ki-67. Gut Liver. 2014;8:13–23.
26. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer J Int Cancer. 2010;127:2893–917.
27. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.
28. Draht MX, Riedl RR, Niessen H, Carvalho B, Meijer GA, Herman JG, et al. Promoter CpG island methylation markers in colorectal cancer: the road ahead. Epigenomics. 2012;4:179–94.
29. Ni C, Zhang Z, Zhu X, Liu Y, Qu D, Wu P, et al. Prognostic value of cd166 expression in cancers of the digestive system: a systematic review and meta-analysis. PLoS One. 2013;8:e70958.
30. Wang K, Xu J, Zhang J, Huang J. Prognostic role of cd133 expression in colorectal cancer: a meta-analysis. BMC Cancer. 2012;12:573.
31. de Graeff P, Crijns AP, Ten Hoor KA, Klip HG, Hollema H, Oien K, et al. The erbb signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer. 2008;99:341–9.
32. Kaptain S, Tan LK, Chen B. Her-2/neu and breast cancer. Diagn Mol Pathol Am J Surg Pathol B. 2001;10:139–52.
33. Ishikawa T, Kobayashi M, Mai M, Suzuki T, Ooi A. Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization. Am J Pathol. 1997;151:761–8.
34. Jorgensen JT. Targeted HER2 treatment in advanced gastric cancer. Oncology. 2010;78:26–33.
35. McKenzie SJ, DeSombre KA, Bast BS, Hollis DR, Whitaker RS, Berchuck A, et al. Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer. Cancer. 1993;71:3942–6.